Journal article
Lower Treatment Blood Pressure Is Associated With Greatest Reduction in Hematoma Growth After Acute Intracerebral Hemorrhage
Hisatomi Arima, Craig S Anderson, Ji Guang Wang, Yining Huang, Emma Heeley, Bruce Neal, Mark Woodward, Christian Skulina, Mark W Parsons, Bin Ping, Qing Ling Tao, Yue Chun Li, Jian Dong Jiang, Li Wen Tai, Jin Li Zhang, En Xu, Yan Cheng, Lewis B Morgenstern, John Chalmers
HYPERTENSION | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010
Abstract
The pilot phase of the Intensive Blood Pressure Reduction in Acute Cerebral Haemorrhage Trial (INTERACT) showed that rapid blood pressure (BP) lowering can attenuate hematoma growth in acute intracerebral hemorrhage. We sought to define the systolic BP level associated with greatest attenuation of hematoma growth. INTERACT included 404 patients with computed tomographic-confirmed intracerebral hemorrhage, elevated systolic BP (150 to 220 mm Hg), and capacity to commence BP lowering treatment within 6 hours of onset. Computed tomography was done at baseline and at 24 hours using standardized techniques, with digital images analyzed centrally, blinded to clinical data. Associations of baseline..
View full abstractGrants
Awarded by National Health and Medical Research Council of Australia
Funding Acknowledgements
The INTERACT was supported by a program grant (358395) from the National Health and Medical Research Council of Australia.H.A. holds a postdoctoral research fellowship from the University of Sydney. C.S.A. holds a senior principal research fellowship from the National Health and Medical Research Council and has received consulting and lecture fees from Astra Zeneca, Boehringer Ingelheim, Novo Nordisk, Sanofi-Aventis, and Servier. J.G.W. has received consulting and lecture fees from Astra-Zeneca, Novartis, Omron, Pfizer, and Servier. B.N. has received consulting fees from Pfizer, Roche, and Takeda; lecture fees from Amgen, Astra Zeneca, GlaxoSmithKline, Pfizer, Roche, Sanofi Aventis, Servier, and Tanabe; and research support from Johnson and Johnson, Merck Schering Plough, Servier, and the United Healthcare Group. M.W. has received consulting and conference fees from Astra Zeneca, Roche, Glaxo Smith Kline, Pfizer, and Servier. L.B.M. is on a medical adjudication board for Wyeth. J.C. has received lecture fees and research grants administered through the University of Sydney as coprincipal investigator for the Perindopril Protection against Recurrent Stroke Study and the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation Trial from Servier.